Zdeněk Valenta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zdeněk Valenta has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
Z Skodová
7 shared publicationsR. Poledne
6 shared publicationsZ Písa
6 shared publications- Jana Zvarova
Center of Biomedical Informatics, Prague, Czech Republic
5 shared publications P. Stavek
5 shared publicationsR Poledne
5 shared publications
Latest Publications
- Open Access
- 11 November 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-11
Improving precision of vaccine efficacy evaluation using immune correlate data in time-to-event models
Understanding potential differences in vaccine-induced protection between demographic subgroups is key for vaccine development. Vaccine efficacy evaluation across these subgroups in phase 2b or 3 clinical trials presents challenges due to lack of precision: such trials are typically designed to demonstrate overall efficacy rather than to differentiate its value between subgroups. This study proposes a method for estimating vaccine efficacy using immunogenicity (instead of vaccination status) as a predictor in time-to-event models. The method is applied to two datasets from immunogenicity sub-studies of vaccine phase 3 clinical trials for zoster and dengue vaccines. Results show that using immunogenicity-based estimation of efficacy in subgroups using time-to-event models is more precise than the standard estimation. Incorporating immune correlate data in time-to-event models improves precision in estimating efficacy (i.e., yields narrower confidence intervals), which can assist vaccine developers and public health authorities in making informed decisions.
- 11 November 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-11
Open AccessImproving precision of vaccine efficacy evaluation using immune correlate data in time-to-event models
Understanding potential differences in vaccine-induced protection between demographic subgroups is key for vaccine development. Vaccine efficacy evaluation across these subgroups in phase 2b or 3 clinical trials presents challenges due to lack of precision: such trials are typically designed to demonstrate overall efficacy rather than to differentiate its value between subgroups. This study proposes a method for estimating vaccine efficacy using immunogenicity (instead of vaccination status) as a predictor in time-to-event models. The method is applied to two datasets from immunogenicity sub-studies of vaccine phase 3 clinical trials for zoster and dengue vaccines. Results show that using immunogenicity-based estimation of efficacy in subgroups using time-to-event models is more precise than the standard estimation. Incorporating immune correlate data in time-to-event models improves precision in estimating efficacy (i.e., yields narrower confidence intervals), which can assist vaccine developers and public health authorities in making informed decisions.
- Open Access
- 30 April 2024
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 24 (1) , 1-15
Elucidating vaccine efficacy using a correlate of protection, demographics, and logistic regression
Background: Vaccine efficacy (VE) assessed in a randomized controlled clinical trial can be affected by demographic, clinical, and other subject-specific characteristics evaluated as baseline covariates. Understanding the effect of covariates on efficacy is key to decisions by vaccine developers and public health authorities. Methods: This work evaluates the impact of including correlate of protection (CoP) data in logistic regression on its performance in identifying statistically and clinically significant covariates in settings typical for a vaccine phase 3 trial. The proposed approach uses CoP data and covariate data as predictors of clinical outcome (diseased versus non-diseased) and is compared to logistic regression (without CoP data) to relate vaccination status and covariate data to clinical outcome. Results: Clinical trial simulations, in which the true relationship between CoP data and clinical outcome probability is a sigmoid function, show that use of CoP data increases the positive predictive value for detection of a covariate effect. If the true relationship is characterized by a decreasing convex function, use of CoP data does not substantially change positive or negative predictive value. In either scenario, vaccine efficacy is estimated more precisely (i.e., confidence intervals are narrower) in covariate-defined subgroups if CoP data are used, implying that using CoP data increases the ability to determine clinical significance of baseline covariate effects on efficacy. Conclusions: This study proposes and evaluates a novel approach for assessing baseline demographic covariates potentially affecting VE. Results show that the proposed approach can sensitively and specifically identify potentially important covariates and provides a method for evaluating their likely clinical significance in terms of predicted impact on vaccine efficacy. It shows further that inclusion of CoP data can enable more precise VE estimation, thus enhancing study power and/or efficiency and providing even better information to support health policy and development decisions.
- 30 April 2024
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 24 (1) , 1-15
Open AccessElucidating vaccine efficacy using a correlate of protection, demographics, and logistic regression
Background: Vaccine efficacy (VE) assessed in a randomized controlled clinical trial can be affected by demographic, clinical, and other subject-specific characteristics evaluated as baseline covariates. Understanding the effect of covariates on efficacy is key to decisions by vaccine developers and public health authorities. Methods: This work evaluates the impact of including correlate of protection (CoP) data in logistic regression on its performance in identifying statistically and clinically significant covariates in settings typical for a vaccine phase 3 trial. The proposed approach uses CoP data and covariate data as predictors of clinical outcome (diseased versus non-diseased) and is compared to logistic regression (without CoP data) to relate vaccination status and covariate data to clinical outcome. Results: Clinical trial simulations, in which the true relationship between CoP data and clinical outcome probability is a sigmoid function, show that use of CoP data increases the positive predictive value for detection of a covariate effect. If the true relationship is characterized by a decreasing convex function, use of CoP data does not substantially change positive or negative predictive value. In either scenario, vaccine efficacy is estimated more precisely (i.e., confidence intervals are narrower) in covariate-defined subgroups if CoP data are used, implying that using CoP data increases the ability to determine clinical significance of baseline covariate effects on efficacy. Conclusions: This study proposes and evaluates a novel approach for assessing baseline demographic covariates potentially affecting VE. Results show that the proposed approach can sensitively and specifically identify potentially important covariates and provides a method for evaluating their likely clinical significance in terms of predicted impact on vaccine efficacy. It shows further that inclusion of CoP data can enable more precise VE estimation, thus enhancing study power and/or efficiency and providing even better information to support health policy and development decisions.
- 4 April 2023
- Published by H1 Connect
Faculty Opinions recommendation of A flexible class of generalized joint frailty models for the analysis of survival endpoints.
In an analogy to establishing the framework of generalised linear models, the authors introduce generalised survival models which use a link function to relate survival function to a linear predictor including time and covariate effects. Through various choices of the link function, they obtain different classes of survival models, such as, e.g., proportional hazards, additive hazards, proportional odds and probit models. The first two models mentioned were further extended via smoothing for estimating the baseline hazard and fitting time-varying effects. The article focuses on extending the Cox proportional model for the analysis of correlated time-to-event outcomes using a shared-frailty approach, as well as taking on a joint modelling approach (‘joint frailty’) for the simultaneous analysis of recurrent events. Parameter estimation is provided under penalised framework, and the class of models is available for download from the Comprehensive R Archive Network under the package name ‘frailtypack’.
- 4 April 2023
- Published by H1 Connect
Faculty Opinions recommendation of A flexible class of generalized joint frailty models for the analysis of survival endpoints.
In an analogy to establishing the framework of generalised linear models, the authors introduce generalised survival models which use a link function to relate survival function to a linear predictor including time and covariate effects. Through various choices of the link function, they obtain different classes of survival models, such as, e.g., proportional hazards, additive hazards, proportional odds and probit models. The first two models mentioned were further extended via smoothing for estimating the baseline hazard and fitting time-varying effects. The article focuses on extending the Cox proportional model for the analysis of correlated time-to-event outcomes using a shared-frailty approach, as well as taking on a joint modelling approach (‘joint frailty’) for the simultaneous analysis of recurrent events. Parameter estimation is provided under penalised framework, and the class of models is available for download from the Comprehensive R Archive Network under the package name ‘frailtypack’.
- 18 April 2022
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (4) , 940-947
Kidney Graft Failure and Patient Survival Modelling Based on Competing Risks Under Nonproportional Hazards
- 18 April 2022
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (4) , 940-947
Kidney Graft Failure and Patient Survival Modelling Based on Competing Risks Under Nonproportional Hazards
- 1 February 2022
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 95, 28-34
Tremor associated with similar structural networks in Parkinson's disease and essential tremor
- 1 February 2022
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 95, 28-34
Tremor associated with similar structural networks in Parkinson's disease and essential tremor
- 5 January 2022
- Published by H1 Connect
Faculty Opinions recommendation of A review of the use of time-varying covariates in the Fine-Gray subdistribution hazard competing risk regression model.
The focus of this paper is on the use of time-varying covariates with the Fine-Gray subdistribution hazard model. However, similar issues arise with the conventional Cox proportional hazards model in the absence of competing risks. When including time-varying covariates in a conventional Cox regression model, one can still estimate the effect of covariates on the hazard function. However, one may lose the ability to estimate the effect of covariates on the survival function and to make inferences about the direction of the effect of the covariate on the incidence of the outcome.
- 5 January 2022
- Published by H1 Connect
Faculty Opinions recommendation of A review of the use of time-varying covariates in the Fine-Gray subdistribution hazard competing risk regression model.
The focus of this paper is on the use of time-varying covariates with the Fine-Gray subdistribution hazard model. However, similar issues arise with the conventional Cox proportional hazards model in the absence of competing risks. When including time-varying covariates in a conventional Cox regression model, one can still estimate the effect of covariates on the hazard function. However, one may lose the ability to estimate the effect of covariates on the survival function and to make inferences about the direction of the effect of the covariate on the incidence of the outcome.
- 5 January 2021
- Published by H1 Connect
Faculty Opinions recommendation of Probabilistic machine learning and artificial intelligence.
The probabilistic framework is a tool used to handle and display uncertainties in scientific models; it is important in many fields, including robotics and artificial intelligence, machine learning, and scientific data analysis. Many new and exciting advances in this field are discussed, such as Bayesian optimisation, data compression, automatic model discovery and probabilistic programming, as well as an overview of the framework itself. The author reviews the reasons why probabilistic programming could prove revolutionary for machine intelligence and scientific modelling and the task of automatic discovery of interpretable models from data. He argues that probabilistic modelling will continue to play a central role in the development of ever more powerful machine learning and artificial intelligence systems.
- 5 January 2021
- Published by H1 Connect
Faculty Opinions recommendation of Probabilistic machine learning and artificial intelligence.
The probabilistic framework is a tool used to handle and display uncertainties in scientific models; it is important in many fields, including robotics and artificial intelligence, machine learning, and scientific data analysis. Many new and exciting advances in this field are discussed, such as Bayesian optimisation, data compression, automatic model discovery and probabilistic programming, as well as an overview of the framework itself. The author reviews the reasons why probabilistic programming could prove revolutionary for machine intelligence and scientific modelling and the task of automatic discovery of interpretable models from data. He argues that probabilistic modelling will continue to play a central role in the development of ever more powerful machine learning and artificial intelligence systems.
- 28 April 2020
- Published by H1 Connect
- Vol. 38 (24)
Faculty Opinions recommendation of Mediation analysis of time-to-event endpoints accounting for repeatedly measured mediators subject to time-varying confounding.
In this article, we will present statistical methods to assess to what extent the effect of a randomised treatment (versus control) on a time-to-event endpoint might be explained by the effect of treatment on a mediator of interest, a variable that is measured longitudinally at planned visits throughout the trial. In particular, we will show how to identify and infer the path-specific effect of treatment on the event time via the repeatedly measured mediator levels. The considered proposal addresses complications due to patients dying before the mediator is assessed, due to the mediator being repeatedly measured, and due to posttreatment confounding of the effect of the mediator by other mediators. We illustrate the method by an application to data from the LEADER cardiovascular outcomes trial. © 2019 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd.
- 28 April 2020
- Published by H1 Connect
- Vol. 38 (24)
Faculty Opinions recommendation of Mediation analysis of time-to-event endpoints accounting for repeatedly measured mediators subject to time-varying confounding.
In this article, we will present statistical methods to assess to what extent the effect of a randomised treatment (versus control) on a time-to-event endpoint might be explained by the effect of treatment on a mediator of interest, a variable that is measured longitudinally at planned visits throughout the trial. In particular, we will show how to identify and infer the path-specific effect of treatment on the event time via the repeatedly measured mediator levels. The considered proposal addresses complications due to patients dying before the mediator is assessed, due to the mediator being repeatedly measured, and due to posttreatment confounding of the effect of the mediator by other mediators. We illustrate the method by an application to data from the LEADER cardiovascular outcomes trial. © 2019 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd.
- 25 June 2019
- Published by H1 Connect
Faculty Opinions recommendation of A review of spline function procedures in R.
This article provides a very useful comprehensive review of spline functions which are available in the R Software for Statistical Computing. The authors identified a set of packages that include functions for spline modelling within a regression framework. Using simulated and real data they provide an introduction to spline modelling and an overview of the most popular spline functions. The authors present a series of simple scenarios of univariate data, where different basis functions are used to identify the correct functional form of an independent variable. Even in simple data, using routines from different packages would lead to different results. The authors provide some guidance to using these powerful tools adequately.
- 25 June 2019
- Published by H1 Connect
Faculty Opinions recommendation of A review of spline function procedures in R.
This article provides a very useful comprehensive review of spline functions which are available in the R Software for Statistical Computing. The authors identified a set of packages that include functions for spline modelling within a regression framework. Using simulated and real data they provide an introduction to spline modelling and an overview of the most popular spline functions. The authors present a series of simple scenarios of univariate data, where different basis functions are used to identify the correct functional form of an independent variable. Even in simple data, using routines from different packages would lead to different results. The authors provide some guidance to using these powerful tools adequately.
- 15 January 2019
- Published by H1 Connect
Faculty Opinions recommendation of Limitations of hazard ratios in clinical trials.
The authors argue that even though the use of hazard ratios (HRs) from the proportional hazards (PHs) models to summarise the results from clinical trials is very popular and the effect estimates may be statistically valid, they are not immediately relevant to individuals as causal effect estimates. At baseline, the assumption of the Cox PH model may be well satisfied, but after baseline there is usually selection bias at work depleting at a higher rate the subjects from the control group when the treatment is indeed effective. In the context of causal inference, the authors argue for the use of survival curve estimates since they may also be used to calculate effect estimates with a causal interpretation, such as restricted mean survival time, or RMST difference reported at several time points.
- 15 January 2019
- Published by H1 Connect
Faculty Opinions recommendation of Limitations of hazard ratios in clinical trials.
The authors argue that even though the use of hazard ratios (HRs) from the proportional hazards (PHs) models to summarise the results from clinical trials is very popular and the effect estimates may be statistically valid, they are not immediately relevant to individuals as causal effect estimates. At baseline, the assumption of the Cox PH model may be well satisfied, but after baseline there is usually selection bias at work depleting at a higher rate the subjects from the control group when the treatment is indeed effective. In the context of causal inference, the authors argue for the use of survival curve estimates since they may also be used to calculate effect estimates with a causal interpretation, such as restricted mean survival time, or RMST difference reported at several time points.